IMGN853

DRUG2 trials

Sponsors

Alessandro Santin, Dana-Farber Cancer Institute

Conditions

Endometrial Cancer

Phase 2

Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer

RecruitingNCT03832361

Alessandro SantinEndometrial Cancer

Start: 2020-07-15End: 2028-10-01Target: 50Updated: 2026-06-26

A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)

Active, not recruitingNCT03835819

Dana-Farber Cancer InstituteEndometrial Cancer

Start: 2020-01-02End: 2027-02-01Updated: 2026-06-01

Related Papers

Mirvetuximab soravtansine plus pembrolizumab in recurrent folate receptor alpha-positive uterine serous carcinoma: a phase II trial

Nature Communications2026-03-26

Abstract CT008: A phase 2, two-stage study of mirvetuximab soravtansine (IMGN853) in combination with pembrolizumab in patients with microsatellite stable (MSS) recurrent or persistent endometrial cancer

Cancer Research2024-04-0511 citations

Abstract B013: Folate receptor alpha (FRa) expression and correlation with other molecular alterations in high grade serous endometrial cancer (EC)

Clinical Cancer Research2024-03-01

TP015/#1566 A phase 2, two-stage, study of mirvetuximab soravtansine (IMGN853) in combination with pembrolizumab in patients with microsatellite stable (MSS) recurrent or persistent endometrial cancer (EC)

2022-12-012 citations

A phase 2, two-stage study of mirvetuximab soravtansine (IMGN853) in combination with pembrolizumab in patients with microsatellite stable (MSS) endometrial cancer (EC).

Journal of Clinical Oncology2021-05-203 citations